Amgen and Novartis have expanded their collaboration with Banner Alzheimer’s Institute (BAI) to initiate a new trial – the Alzheimer’s Prevention Initiative (API) Generation Study 2. This trial will determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer’s disease symptoms in a high-risk population. BACE1 is an enzyme that plays an important role in the production of Amyloid β, a protein which accumulates in the brains of individuals with Alzhei...